BMC complementary medicine and therapies · 2025
Nano-curcumin potentiates antitumor immunity in prostate cancer via co-culture with adipose-derived mesenchymal stem cells.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Zeynali Farid, Tehran Melika Hadad, Faraji Fatemeh, Mahmoudi Mahmoud, Tabasi Nafiseh Sadat, Ghoreyshi Sevda, Arab Fahimeh Lavi
Аннотация
BACKGROUND: Curcumin is a polyphenolic compound from Curcuma longa that exhibits immunoregulatory and anti-cancer properties. It is formulated as nano-curcumin. Mesenchymal stem cells (MSCs) also show anticancer effects and can potentially activate resting immune cells. This study investigates the combined effects of nano-curcumin and adipose-derived mesenchymal stem cells (ASCs) on peripheral blood mononuclear cells (PBMCs) isolated from prostate cancer (PCa) patients.
METHODS: ASCs were isolated and characterized. PBMCs were isolated from patients and co-cultured with and without ASCs in the presence of different concentrations of nano-curcumin to examine cell survival using the MTT assay. Based on the results of the MTT assay, selected concentrations of nano-curcumin were used to investigate apoptosis and cell subpopulations of PBMCs in co-culture with ASCs using apoptosis assay and flow cytometry.
RESULTS: Nano-curcumin increased PBMC survival at concentrations of 3, 6, 12, 25, and 50 µM in co-culture with ASCs. In the absence of ASCs, a significant increase in PBMC survival was observed at concentrations of 6, 12, 25, 50, and100 µM. Concentrations of 6 and 12 µM caused a significant reduction in apoptosis. A concentration of 12 µM increased the number of CD3+CD4+ cells, and the number of CD3+CD8+ cells increased at concentrations of 6 and 25 µM. At a concentration of 25 µM, the number of CD45+CD19+ cells was significantly increased.
CONCLUSION: Nano-curcumin in combination with ASCs has the potential to affect immune cells, indicating its potential as a complementary therapy for use in cancer. Further research is required to confirm these findings.
METHODS: ASCs were isolated and characterized. PBMCs were isolated from patients and co-cultured with and without ASCs in the presence of different concentrations of nano-curcumin to examine cell survival using the MTT assay. Based on the results of the MTT assay, selected concentrations of nano-curcumin were used to investigate apoptosis and cell subpopulations of PBMCs in co-culture with ASCs using apoptosis assay and flow cytometry.
RESULTS: Nano-curcumin increased PBMC survival at concentrations of 3, 6, 12, 25, and 50 µM in co-culture with ASCs. In the absence of ASCs, a significant increase in PBMC survival was observed at concentrations of 6, 12, 25, 50, and100 µM. Concentrations of 6 and 12 µM caused a significant reduction in apoptosis. A concentration of 12 µM increased the number of CD3+CD4+ cells, and the number of CD3+CD8+ cells increased at concentrations of 6 and 25 µM. At a concentration of 25 µM, the number of CD45+CD19+ cells was significantly increased.
CONCLUSION: Nano-curcumin in combination with ASCs has the potential to affect immune cells, indicating its potential as a complementary therapy for use in cancer. Further research is required to confirm these findings.